As researchers try to make sense of “open-label” placebos—fake drugs that proudly announce their fakeness—the mysterious effect is starting to show up beyond the world of medicine.

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies ...

On Saturday April 5, Anavex announced data from their open-label extension trial, ATTENTION-AD, for early Alzheimer's Disease presented at the AD/PDTM 2025 Conference. ATTENTION-AD is a follow-on ...

Crinecerfont is associated with sustained reductions in androstenedione and GC doses at 1 year in congenital adrenal hyperplasia.

White-label solutions are emerging as a viable alternative, allowing businesses to enter the market quickly and cost-effectively. Responding to Market Trends: Control and Customization Take Priority ...

However, despite the increased shareholding, Blue Label maintains it does not have de facto control of Cell C. The company holds 49.53% of shareholder voting rights and can appoint four out of 12 ...

In this open-label, controlled trial, we randomly assigned adults who were smoking at least five tobacco cigarettes per day and who wanted to set a quit date to an intervention group, which ...

Patients and Methods Trial Design and Participants The K-Umbrella GC study was an open-label, randomized, multiarm, phase II trial with a novel umbrella trial design (biomarker-integrated multiarm ...

BEACON and Open-Label Extension Study Design and Data Summary: ...